[Advances in study of murine double minute 2/p53 passway with breast cancer]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The p53 tumor suppressor gene is crucial for preventing cancer.
• Aberrant p53 regulation, often involving the MDM2 oncoprotein, is common in breast cancer.
• The MDM2/p53 pathway significantly impacts breast cancer development and treatment.

Purpose of the Study:

• This review summarizes the role of the MDM2/p53 pathway in breast cancer.
• It explores the pathway's relationship with pathological features, treatment, and patient outcomes.
• Additionally, it examines interactions between the MDM2/p53 pathway and other molecular markers in breast cancer.

Main Methods:

• Literature review of studies on the MDM2/p53 pathway in breast cancer.
• Analysis of the pathway's interactions with molecular markers like PI3K/Akt/mTOR, p14ARF, and Her2/neu.
• Synthesis of information regarding the pathway's influence on breast cancer pathology, therapy, and prognosis.

Main Results:

• Mutations or dysregulation of p53 lead to loss of tumor suppression, prevalent in breast cancer.
• The MDM2/p53 feedback loop is a key regulator in breast cancer.
• Other molecular markers, including PI3K/Akt/mTOR, p14ARF, and Her2/neu, influence the MDM2/p53 pathway in breast cancer.

Conclusions:

• The MDM2/p53 pathway is integral to breast cancer progression and response to therapy.
• Understanding these interactions offers insights into breast cancer pathogenesis and potential therapeutic strategies.
• Further research into the MDM2/p53 pathway and its regulators is essential for improving breast cancer treatment and prognosis.